For decades, cancer genetics has largely been treated as a binary enterprise: a gene is either mutated or it is not, and clinical decisions have often hinged on that simple yes-or-no call. The new findings challenge that framing at scale. By quantifying how much of each mutated gene is present in a tumor — a property captured by the variant allele fraction and related dosage measures — the researchers demonstrated that mutations are not uniform events but graded biological forces whose intensity shapes tumor behavior. A mutation present in a small subset of cells within a tumor may be biologically and clinically very different from the same mutation present in every cell, and the study shows that this difference is measurable, reproducible, and prognostically meaningful across a wide range of cancer types.

The sheer scale of the analysis is central to its power. Individual cancer sequencing studies, even well-designed ones, typically involve hundreds or a few thousand patients, which limits the statistical strength available to detect subtle effects. Smaller cohorts are also vulnerable to confounding: a mutation that appears associated with poor survival in one dataset may simply reflect a different mix of disease stages, treatments, or demographics. By pooling clinical samples on the order of tens of thousands, the team was able to overcome these limitations, controlling for key clinical variables while still detecting robust associations between mutant dosage and outcomes. The result is one of the most comprehensive demonstrations to date that quantitative features of tumor mutations belong in the same conversation as qualitative ones when estimating a patient’s risk.

The concept of mutant dosage has familiar analogies elsewhere in genetics. In inherited disease, the difference between carrying one copy and two copies of a pathogenic allele can dramatically alter severity, a principle long recognized in classical genetics. But in cancer, where tumors are mosaics of genetically distinct cells and where copy-number changes, loss of heterozygosity, and subclonal architecture constantly reshape the mutation landscape, dosage has been harder to pin down. Sequencing technologies now routinely report the fraction of sequencing reads carrying a variant, and that fraction encodes information about how widespread the mutation is within the tumor sample. What the new study shows is that this routinely measured number, often treated as a technical byproduct, is in fact a clinical signal in its own right.

A particularly striking dimension of the work concerns metastasis. Not all cancers spread randomly; lung cancers have a well-documented affinity for the brain, adrenal glands, and bone, while colorectal cancers frequently seed the liver, and breast cancers show their own organ-specific patterns. The mechanisms behind this tropism — sometimes described through the “seed and soil” hypothesis, in which tumor cells act as seeds whose success depends on the soil of the destination organ — have been studied intensively, but the genetic determinants remain incompletely mapped. The new analysis indicates that the dosage of specific mutations is associated with where tumors ultimately metastasize, suggesting that the clonal dominance of certain driver alterations may equip cancer cells for survival and growth in particular organ environments. In other words, how extensively a mutation has swept through a tumor may help predict not just whether cancer will spread, but where.

The prognostic implications follow a similar logic. Mutant dosage reflects, in part, the clonal architecture of a tumor: a mutation present at high fraction is likely clonal, present in the founding population of the cancer, whereas a low-fraction mutation may be subclonal, acquired later in the tumor’s evolutionary history. Clonal versus subclonal status has known prognostic relevance in several cancer types, but the new study extends and systematizes this insight across a much broader patient population. Mutations that have reached high dosage may indicate that a driver event occurred early and conferred a strong growth advantage, producing a tumor whose entire cellular population carries that alteration — a configuration that the data link to distinct patterns of patient survival compared with tumors in which the same mutation remains confined to a minority of cells.

The study also has practical relevance for the growing field of liquid biopsy and clinical sequencing. High-throughput panel sequencing is now standard in many oncology centers, and every clinical report already contains variant allele fractions, even if they are rarely interpreted quantitatively. The findings suggest that this information could be incorporated into prognostic models and treatment planning. For example, two patients whose tumors carry the same driver mutation might currently receive the same risk assessment and even the same therapeutic strategy, despite one mutation being clonal and the other subclonal. If dosage information can refine risk stratification, it could influence decisions about surveillance intensity, adjuvant therapy, and the sequencing of systemic treatments, all without requiring any new tests — only a new way of reading the data already in hand.

Methodologically, the work reflects the maturation of large-scale real-world genomic data analysis. Clinical samples come with noise: variable tumor purity, differing sequencing platforms, heterogeneous coverage, and inconsistent metadata. Converting raw variant allele fractions into meaningful dosage estimates requires careful normalization for tumor purity and copy number, since a variant present in all tumor cells will still show a reduced allele fraction if the sample contains a large admixture of normal cells or if the mutant allele has been copied or lost along with its chromosome segment. Handling these technical factors at the scale of tens of thousands of samples demands rigorous computational pipelines and statistical modeling, and the robustness of the reported associations across such a heterogeneous clinical corpus suggests the underlying biology is strong enough to survive substantial measurement noise.

The evolutionary interpretation of the findings is equally compelling. Tumors evolve by Darwinian selection, and the dosage of a mutation is a fossil record of that evolutionary process. A high-dosage mutation marks an early, successful clone; low-dosage mutations mark recent experiments, some of which may be on their way to dominance. Because metastasis is itself an evolutionary bottleneck — only a small subset of tumor cells successfully seed distant sites — the composition of mutations within the primary tumor, including their dosage, plausibly shapes which lineages are available to undertake that journey and which organ environments they can exploit. The observed links between dosage and metastatic tropism therefore fit naturally within modern models of cancer as an evolving ecosystem rather than a static catalog of mutations.

Looking forward, the study opens several avenues for clinical translation. Prospective studies will be needed to validate mutant dosage as an independent prognostic biomarker within specific cancer types and treatment contexts, and to determine whether dosage-based stratification improves upon existing staging and genomic risk models. Researchers will also want to identify the mechanisms by which high-dosage alterations promote organ-specific metastasis, potentially revealing vulnerabilities that could be targeted therapeutically. If the associations hold up, mutant dosage could become a standard column in molecular tumor reports, adding quantitative nuance to a discipline that has often relied on mutation presence alone. At a time when genomic sequencing of tumors has become routine, the message of this work is that the data needed for deeper clinical insight are already being generated every day — they simply need to be read with the sophistication they deserve. The transformation of variant allele fraction from a technical footnote into a prognostic and metastatic signal is a reminder that in cancer genomics, as in physics, the most consequential discoveries sometimes come not from new measurements but from new ways of interpreting the numbers we already have.

The study, published in Genome Medicine, examined acquired resistance to CDK4/6 inhibitors, drugs that have transformed the treatment of advanced estrogen receptor-positive breast cancer. These medicines are commonly given with endocrine therapy, which blocks estrogen signaling or interferes with the estrogen receptor. CDK4/6 inhibitors attack a different part of the growth machinery: they restrain cyclin-dependent kinases 4 and 6, proteins that help push cells from a resting phase into DNA replication. By interrupting this cell-cycle transition, the drugs can slow or stop tumor expansion. Yet most metastatic tumors eventually resume growing. Activating ESR1 mutations are already recognized as a frequent route to resistance against endocrine therapy, but their independent contribution to resistance against CDK4/6 inhibition has been far less clear.

To isolate that contribution, the researchers built an isogenic model using MCF7 breast-cancer cells. The cells were genetically matched except for the form of estrogen receptor they carried: one group expressed the normal, or wild-type, receptor, while another expressed the Y537S mutant form of ER, a common activating ESR1 mutation. This design allowed the investigators to compare resistance evolution while holding much of the cellular background constant. They then exposed the cells to either palbociclib or abemaciclib, two CDK4/6 inhibitors, and followed the populations over time. The team combined high-complexity DNA barcoding with molecular profiling, effectively giving thousands of cancer-cell lineages unique genetic “names” that could be tracked as treatment removed some populations and allowed others to expand.

This lineage-tracing strategy captured a feature that conventional drug-sensitivity tests can miss. A tumor may appear to be a single mass, but it is typically a crowded ecosystem containing many related subclones. Some may already carry mutations that confer a survival advantage, while others may not be genetically resistant but can temporarily alter their behavior when exposed to stress. As treatment continues, the drug changes the population’s environment. Sensitive clones shrink or disappear, resistant clones expand and previously minor populations can become dominant. The researchers observed progressive clonal selection under both inhibitors, with some evolutionary paths diverging and others partially converging on similar resistant states. In other words, different starting populations could reach overlapping biological solutions, even though the precise clones and regulatory changes involved were not identical.

The effect of the estrogen-receptor mutation was especially pronounced during selection with palbociclib. In cells carrying ER-Y537S, the mutation substantially reshaped both clonal evolution and epigenetic evolution—the changes in chromatin accessibility and gene regulation that influence which genes a cell can use without altering the DNA sequence itself. The same mutation had a weaker effect under abemaciclib selection. This difference is important because palbociclib and abemaciclib inhibit the same broad protein targets but are not biologically interchangeable. They differ in potency, selectivity, dosing behavior and effects on cell-cycle control, and abemaciclib can inhibit additional kinases at clinically relevant concentrations. The results indicate that each drug creates its own selective landscape, favoring distinct combinations of pre-existing traits and treatment-induced adaptations.

The study also showed that resistance is not explained by genetics alone. Single-cell RNA sequencing revealed pronounced transcriptional heterogeneity as cells were passaged and exposed to drug selection. Individual cells within the same resistant population could occupy different functional states, including states associated with altered proliferation, stress responses, lineage programs and cellular plasticity. Plasticity refers to a cell’s ability to shift its phenotype in response to changing conditions. A cell that temporarily enters a slow-cycling or altered regulatory state may survive therapy without immediately acquiring a new resistance mutation. If treatment persists, that state can provide time for more stable genetic or epigenetic changes to emerge. This layered process helps explain why resistance can develop gradually and why a resistant tumor may remain vulnerable to a different therapeutic pressure.

The researchers extended their analysis beyond cultured cells by studying patient tumor samples. They found that ESR1 mutations were enriched in clinical tumors that had acquired resistance to CDK4/6 inhibitors. In paired biopsies taken before and after treatment, mutant cancer-cell populations expanded until they approached clonality, meaning that the mutation was present in nearly all of the sampled tumor cells. Such expansion is a strong sign of treatment-driven selection: the mutation may have been present in only a minority of cells initially, but therapy created conditions in which those cells gained a decisive advantage. The finding does not mean that every resistant tumor is dominated by an ESR1 mutation, nor that the mutation alone explains resistance. Instead, it places the receptor mutation within a broader evolutionary process involving competing clones, adaptable cell states and drug-specific pressures.

Experiments in mice added another layer to the picture by tracing barcoded cancer cells in mammary tumors, local recurrences and distant metastases. The investigators observed site-specific clonal outgrowth in tumors carrying mutant estrogen receptors. Different anatomical sites favored different subclones, suggesting that the tissue environment can act as another filter during cancer evolution. Some subpopulations overlapped between metastatic lesions and CDK4/6-inhibitor-resistant tumors, supporting the possibility that particular cancer-cell groups can perform a dual role: surviving treatment in one setting while also possessing traits that help them colonize distant organs. However, the overlap was only partial. Resistance and metastatic spread therefore appear related but not identical, with each process selecting for some shared and some distinct characteristics.

The implications extend to how oncologists think about treatment after CDK4/6 inhibitor failure. The results argue against viewing resistance as a uniform condition that can be treated with one universal sequence of drugs. Instead, the most effective next therapy may depend on whether a tumor carries an activating ESR1 mutation, which CDK4/6 inhibitor was used first and which cellular states emerged during treatment. Molecular tests that identify receptor mutations are already relevant to endocrine-treatment decisions, but the new work suggests they could also help interpret the evolutionary history of CDK4/6 inhibitor resistance. Future strategies might combine drugs that target estrogen-receptor signaling with agents aimed at cell-cycle control or the adaptive states that allow cancer cells to persist. Such approaches will require clinical testing, because findings from engineered cell models and mouse xenografts cannot by themselves predict patient benefit.

The central message is that cancer resistance is a moving target rather than a fixed lock that one key fails to open. By combining lineage tracing, DNA sequencing, chromatin analysis and single-cell transcriptomics, the researchers were able to watch resistant populations emerge at several biological scales—from individual clones to shifting gene-expression states and tumor growth in different organs. Their findings show that ESR1 mutation status and inhibitor choice jointly shape the route a tumor takes under treatment. Mapping those routes could make resistance more predictable and could encourage treatment plans designed not merely to kill the dominant cancer population, but also to prevent minor, adaptable clones from becoming the next dominant threat.

Subject of Research: Clonal evolution and adaptive cell states underlying CDK4/6 inhibitor resistance in estrogen receptor-positive breast cancer

Article Title: ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance

Article References: Guarducci, C., Abravanel, D., Russo, D. et al. “ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance.” Genome Medicine (2026). Original research article

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01690-2

Keywords: estrogen receptor-positive breast cancer, ESR1 mutations, CDK4/6 inhibitor resistance, palbociclib, abemaciclib, clonal evolution, cancer cell plasticity, metastatic colonization